Status:
COMPLETED
Effect of Addition Oral Montelukast to Standard Treatment in Acute Asthma in Hospitalized Preschool Children
Lead Sponsor:
Kecioren Education and Training Hospital
Conditions:
Acute Asthma
Acute Wheezy Bronchitis
Eligibility:
All Genders
6-60 years
Phase:
PHASE4
Brief Summary
Leukotriene receptor antagonists (LTRAs) are well established in the management of outpatient asthma. Montelukast is a potent, specific, orally active, cysteinyl leukotriene receptor antagonist with a...
Detailed Description
Background: Montelukast is a potent, specific, orally active, cysteinyl leukotriene receptor antagonist with a rapid onset of action. Objective: To evaluate the effect of the addition of a single dos...
Eligibility Criteria
Inclusion
- Medical history of at least 4 wheezing attacks
- Children with the ages of 6-60 months
- Children whose parents accept to give written informed consent
Exclusion
- Chronic diseases (e.g. malnutrition, anatomic malformation of the respiratory tract, chronic lung or heart disease, gastroesophageal reflux disease and cystic fibrosis)
- Children with a history of chronic drug use (e.g. antiepileptics and immune suppressives)
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03369119
Start Date
August 1 2011
End Date
December 1 2012
Last Update
December 11 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kecioren Education and Training Hospital
Ankara, Keçiören, Turkey (Türkiye), 06380